查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2006501

微量殘存疾病檢測市場：2026-2032年全球市場預測（依檢測類型、檢體類型、應用領域及最終用戶產業分類）

Minimal Residual Disease Testing Market by Test Type, Sample Type, Application Areas, End-User Vertical - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，微量殘存疾病(MRD) 檢測市場價值將達到 20.8 億美元，到 2026 年將成長至 23.1 億美元，到 2032 年將達到 44.7 億美元，年複合成長率為 11.55%。

主要市場統計數據
基準年 2025 20.8億美元
預計年份：2026年 23.1億美元
預測年份 2032 44.7億美元
複合年成長率 (%) 11.55%

微量殘存疾病（MRD）檢測已從一項專門的檢查性檢測發展成為一項關鍵的臨床工具，可用於評估血液系統惡性腫瘤和某些固態腫瘤的預後、確定治療強度以及製定適應性治療策略。臨床醫生和實驗室管理人員現在不僅將MRD視為一種生物標記物，更將其視為影響緩解評估、復發監測以及新治療方法合格的決策工具。因此，診斷領域正在引入更廣泛的分析方法、更高的靈敏度閾值以及旨在將結果整合到快速臨床路徑中的工作流程。

更靈敏的檢測平台的引入以及臨床試驗終點與微小殘留疾病（MRD）狀態的一致性正在加速MRD檢測在臨床實踐中的應用。同時，檢體處理、品管和報告標準的同步進步正在降低實驗室間的差異。因此，MRD檢測處於臨床緊迫性和技術創新的交匯點，需要在影響治療選擇的時間範圍內獲得可重複且具有臨床應用價值的結果。因此，對於相關人員，了解分析能力、臨床有效性和操作準備之間的相互關係至關重要。

微量殘存疾病)檢測的變革性轉變，是由分析技術的創新、臨床有效性的建立以及與治療決策框架的整合所驅動的。

微小殘留疾病（MRD）領域正經歷一場變革，這場變革的驅動力來自高靈敏度分子技術、精密細胞檢測和數位化分析的融合。諸如針對低等位基因頻率檢測的靶向次世代定序panel、用於絕對定量分析的數位化PCR方法以及針對標準化免疫表現型分析最佳化的多參數流式細胞技術等創新技術，共同提高了檢測極限。同時，檢體儲存、集中參考檢測和跨平台檢驗研究的改進，正在降低檢查室間差異，並增強臨床醫生對MRD檢測結果的信心。

評估 2025 年美國關稅政策調整對供應鏈成本結構和臨床獲得微量殘存疾病(MRD) 診斷的累積影響。

2025年實施的關稅調整為依賴全球一體化供應鏈獲取設備、試劑和耗材的相關人員帶來了新的營運複雜性。進口專用設備和檢測組件關稅的提高推高了單位成本，促使獎勵重新評估籌資策略。對於臨床檢查室和診斷設備製造商而言，這些成本壓力可能導致利潤率下降、昂貴設備的更換週期延長，並迫使其重新思考定價和服務模式，以在不影響臨床服務的前提下維持業務永續營運。

關鍵細分洞察顯示了測試方式、臨床應用和最終用戶領域如何結合起來，從而確定採用優先順序和價值創造。

從細分市場的觀點來看，分析方法、臨床適應症和終端用戶類型如何相互作用，從而塑造微小殘留疾病（MRD）檢測的引入路徑和價值創造，這一點顯而易見。染色體微陣列和螢光原位雜合技術（FISH）等細胞遺傳學方法在檢測某些血液疾病的結構異常方面仍然發揮著至關重要的作用，同時它們也與流式細胞技術技術並存，後者的多參數和單參數平台提供了互補的細胞解析度。分子檢測方法佔據核心地位。標靶次世代定序panel和全基因測序為基於突變的MRD評估提供了靈敏度和廣度，而數位PCR和定量PCR則能夠對預定義標靶進行快速且經濟高效的定量分析。

區域戰略情報：繪製北美、歐洲、中東和非洲以及亞太地區的採用趨勢、基礎設施優勢、償還趨勢和協作生態系統。

區域趨勢對微生物參考診斷（MRD）的普及應用有顯著影響，因為不同地區的管理體制、報銷機制和檢查室基礎設施差異很大。在美洲，成熟的參考實驗室和高密度的臨床試驗支持了新型MRD平台的快速普及。然而，支付方覆蓋範圍的差異可能會限制其在臨床環境之外的常規應用。此外，該地區的診斷網路也發揮創新中心的作用，促進臨床中心與產業界之間的夥伴關係，從而加速實證醫學證據的產生和應用。

專注夥伴關係、垂直整合、證據產生和服務差異化策略，這些策略塑造了競爭定位，並從企業層面提供了關鍵洞察。

現代微生物診斷（MRD）領域的競爭動態呈現出專業化與整合並存的趨勢。診斷開發公司和平台提供者透過分析靈敏度、檢測穩健性和與臨床工作流程的便利整合來脫穎而出，而試劑供應商則在供應鏈的一致性、批間可靠性和合規性方面展開競爭。平台整合商和臨床實驗室網路正日益提供配套服務，將儀器、軟體驅動的診斷和報告範本結合，以滿足臨床醫生的決策需求。

為幫助產業領導者加快採用、降低風險、協調臨床證據、營運執行和支付方合作，提供可操作且優先考慮的建議。

致力於加速應用最小參考值（MRD）的產業領導者應採取一系列切實可行的舉措，兼顧臨床效用和營運可行性。首先，他們應優先考慮產生可靠的臨床證據，具體做法是將MRD終點納入前瞻性治療試驗，並進行真實世界結局研究，以證明基於MRD的決策如何改善患者預後。其次，他們應透過選擇替代供應商、建立區域庫存緩衝以及考慮高風險組件的本地化生產，來增強供應鏈韌性並降低關稅和物流風險。

透明的調查方法，解釋了資料來源、專家參與、分析框架和檢驗方法，從而深入了解微量殘存疾病(MRD) 檢測。

本分析整合了多方面研究方法的證據，旨在對研究結果進行三角驗證並減少偏差。調查方法結合了對同行評審文獻、臨床指南、監管文件和技術白皮書的系統性回顧，以及對臨床專家、檢查室管理人員、生物製藥開發管理人員和供應鏈專家的有針對性的初步訪談。在數據可用的情況下，將檢測性能數據與已發表的檢驗研究和監管摘要進行橫斷面比較，以評估其一致性和可重複性。

綜合總結了突出機會、營運挑戰和策略重點的結論，這些將塑造微量殘存疾病（MRD）診斷的未來方向。

總之，微小殘留疾病（MRD）檢測正處於一個關鍵節點，分析技術的進步、臨床檢驗工作以及商業策略的整合將推動其實現更廣泛的臨床效用。儘管目前可用的診斷方法提供了一套可根據疾病生物學特徵和醫療服務限制進行調整的工具包，但其成功推廣仍需嚴謹的證據生成、穩健的供應鏈以及與支付方的合作。政策變化，例如關稅和不斷變化的報銷環境，增加了複雜性，需要根據具體情況制定相應的商業化和營運計劃。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：按檢測類型微量殘存疾病檢測市場

  • 細胞遺傳學
    • 染色體微陣列
    • 螢光原位雜合反應（FISH）
  • 流式細胞技術
    • 多參數流式細胞技術
    • 單參數流式細胞技術
  • 次世代定序（NGS）
    • 目標序列
    • 全基因組定序
  • 聚合酵素鏈鎖反應（PCR）
    • 數位PCR
    • 定量PCR

第9章：微量殘存疾病檢測市場—檢體類型

  • 血
    • 電漿
    • 血清
  • 骨髓
  • 腦脊髓液（CSF）
  • 組織切片檢查
  • 尿

第10章：微量殘存疾病檢測的市場應用領域

  • 白血病
    • 急性淋巴性白血病（ALL）
    • 急性骨髓性白血病（AML）
    • 慢性淋巴性白血病（CLL）
  • 淋巴瘤
    • 何傑金氏淋巴瘤
    • 非何傑金氏淋巴瘤
  • 多發性骨髓瘤
  • 固體癌
    • 乳癌
    • 結腸癌

第11章：以最終用戶分類的微量殘存疾病檢測市場

  • 學術和研究機構
  • 生物製藥公司
  • 診斷檢測實驗室
  • 醫院

第12章：微量殘存疾病檢測市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章：微量殘存疾病檢測市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章：微量殘存疾病檢測市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國微量殘存疾病檢測市場

第16章：中國微量殘存疾病檢測市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Adaptive Biotechnologies Corporation
  • Agilus Diagnostics Ltd.
  • Amgen Inc.
  • ARUP Laboratories
  • AstraZeneca PLC
  • Asuragen Inc. by Bio-Techne Corporation
  • Bio-Rad Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • C2I Genomics Inc.
  • Cergentis BV
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • Genetron Holdings Limited
  • GRAIL, LLC by Illumina, Inc.
  • Guardant Health, Inc.
  • Integrated DNA Technologies, Inc.
  • Invivoscribe, Inc.
  • Kite Pharma, Inc. by Gilead Sciences, Inc.
  • Laboratory Corporation of America Holdings
  • Mdxhealth BV
  • MedGenome Inc
  • Mission Bio, Inc.
  • Myriad Genetics, Inc.
  • Natera Inc.
  • NeoGenomics Laboratories, Inc.
  • OPKO Health, Inc.
  • Quest Diagnostics incorporated
  • Sysmex Corporation
  • Veracyte, Inc.
Product Code: MRR-961BA04A2E6C

The Minimal Residual Disease Testing Market was valued at USD 2.08 billion in 2025 and is projected to grow to USD 2.31 billion in 2026, with a CAGR of 11.55%, reaching USD 4.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.08 billion
Estimated Year [2026] USD 2.31 billion
Forecast Year [2032] USD 4.47 billion
CAGR (%) 11.55%

Minimal residual disease (MRD) testing has evolved from a specialized research assay into a pivotal clinical tool that informs prognosis, guides therapeutic intensity, and enables adaptive treatment strategies across hematologic and selected solid tumor indications. Clinicians and laboratory leaders now view MRD not merely as a biomarker but as a decision-making instrument that affects remission assessment, relapse surveillance, and eligibility for novel therapies. Consequently, the diagnostic landscape is responding with a broader array of analytical approaches, enhanced sensitivity thresholds, and workflows designed to integrate results into fast-moving clinical pathways.

The introduction of more sensitive platforms and the alignment of clinical trial endpoints with MRD status have accelerated clinical adoption, while parallel advances in sample handling, quality control, and reporting standards are beginning to reduce variability across testing sites. As a result, MRD testing occupies an intersection of clinical urgency and technological innovation: it must deliver reproducible, clinically actionable results within timelines that influence therapeutic choices. Understanding the interplay between analytical capability, clinical validation, and operational readiness is therefore essential for stakeholders seeking to scale MRD testing from specialized centers to routine care settings.

Transformative shifts redefining minimal residual disease testing driven by analytical innovation clinical validation and integration into therapeutic decision frameworks

The MRD landscape is undergoing transformative shifts driven by convergence between high-sensitivity molecular techniques, refined cellular assays, and digital analytics. Innovations such as targeted next-generation sequencing panels tailored for low-allele-frequency detection, digital PCR approaches that deliver absolute quantitation, and multi-parameter flow cytometry optimized for standardized immunophenotyping are collectively raising the floor of detectability. Concurrently, improvements in sample preservation, centralized reference testing, and cross-platform validation studies are reducing inter-laboratory variance and increasing clinician confidence in MRD readouts.

Beyond raw analytical progress, the integration of MRD into clinical trial design and regulatory pathways is reshaping commercial and clinical incentives. As MRD is increasingly used as an early surrogate endpoint for therapeutic efficacy, sponsors are structuring trials and regulatory engagements to demonstrate how MRD-informed dosing or duration strategies improve patient outcomes. Additionally, digital infrastructure-ranging from laboratory information systems to cloud-based variant interpretation-supports faster result delivery and federated analytics, which in turn enable scalable clinical decision support. Together, these shifts are accelerating MRD from a niche diagnostic towards a standardized element of precision oncology workflows.

Assessing the cumulative effects of United States tariff policy adjustments in 2025 on supply chains cost structures and clinical access to minimal residual disease diagnostics

Tariff changes enacted in 2025 have introduced a new layer of operational complexity for stakeholders that depend on a globally integrated supply chain for instruments, reagents, and consumables. Increased duties on imported specialized equipment and assay components raise unit costs and create incentive pressures to adjust procurement strategies. For clinical laboratories and diagnostic manufacturers, these cost pressures can translate into tighter margins, delayed capital renewal cycles for high-cost instrumentation, and a need to reassess pricing or service models to maintain viability without compromising clinical access.

In addition to direct cost effects, tariffs contribute to supply chain friction that can lengthen lead times for critical reagents and spare parts. Extended replenishment cycles exacerbate inventory risk for high-throughput centers and may compel laboratories to diversify supplier portfolios or to qualify alternative assay formats that rely on locally sourced inputs. Policy responses and commercial mitigations have begun to emerge: some organizations are accelerating regional manufacturing investments, while others are negotiating long-term supply agreements that allocate tariff risk. Clinically, the net effect is uneven; well-resourced systems can absorb short-term disruption through internal buffering and strategic procurement, whereas resource-constrained hospitals and diagnostic networks may face delays or restricted access to advanced MRD platforms. Consequently, stakeholders must factor in tariff-induced cost and availability shifts when projecting technology adoption timelines and when designing resilient operational models.

Key segmentation insights demonstrating how test modalities clinical applications and end-user verticals combine to determine adoption priorities and value creation

A segmentation-aware perspective reveals how analytical modality, clinical indication, and end-user type interact to shape adoption pathways and value creation for MRD testing. Test types such as cytogenetics with chromosomal microarray and FISH retain critical roles for structural aberration detection in certain hematologic contexts, but they coexist with flow cytometry approaches where multi-parameter and single-parameter platforms offer complementary cellular resolution. Molecular modalities occupy a central position: targeted next-generation sequencing panels and whole-genome sequencing provide sensitivity and breadth for mutation-based MRD assessment, while digital PCR and quantitative PCR deliver rapid, cost-efficient quantitation for predefined targets.

Application areas further guide which technical profile is prioritized. In leukemia subtypes including acute lymphoblastic leukemia, acute myeloid leukemia, and chronic lymphocytic leukemia, both molecular and immunophenotypic assays are used to provide orthogonal confirmation of remission status. Lymphoma testing, encompassing Hodgkin's and non-Hodgkin's variants, requires tailored assay designs that balance sensitivity against tumor heterogeneity. Multiple myeloma and selected solid tumors such as breast and colorectal cancer demand bespoke MRD strategies that reflect disease biology and available therapeutic options. Finally, end-user verticals-academic and research institutes, biopharmaceutical companies, diagnostic laboratories, and hospitals-each press unique requirements. Academic centers prioritize methodological innovation and translational research, biopharmaceutical sponsors emphasize standardized assays for clinical trials, diagnostic laboratories focus on throughput and cost-efficiency, and hospitals prioritize turnaround time and integration with electronic medical records. Understanding these interdependencies enables more precise alignment of product design, clinical evidence generation, and commercial models.

Regional strategic intelligence mapping adoption trends infrastructure strengths reimbursement dynamics and collaborative ecosystems across the Americas Europe Middle East & Africa and Asia-Pacific

Regional dynamics exert a strong influence on MRD deployment because regulatory regimes, reimbursement frameworks, and laboratory infrastructure diverge significantly across geographies. In the Americas, established reference laboratories and a high density of clinical trials support relatively rapid uptake of novel MRD platforms, although payer coverage variability can constrain routine use outside of trial settings. The region's diagnostic networks also serve as hubs for innovation, attracting partnerships between clinical centers and industry that accelerate evidence generation and adoption.

Across Europe, the Middle East & Africa, heterogeneity is pronounced: Western European markets benefit from consolidated reimbursement pathways and robust laboratory accreditation systems, while many countries in the Middle East and Africa face capacity constraints that limit access to advanced MRD testing. Collaborative procurement mechanisms and regional reference laboratories are emerging as pragmatic solutions to bridge gaps. In the Asia-Pacific, investment in domestic manufacturing, rising clinical trial activity, and expanding hospital networks are driving uptake, though regulatory timelines and local validation requirements necessitate careful market entry planning. Collectively, these regional patterns imply that commercialization strategies must be tailored: scalable centralized testing models may work in some geographies, whereas decentralized point-of-care or near-patient approaches could better address access and timeliness in others.

Key company-level insights highlighting partnerships vertical integration evidence generation and service differentiation strategies that shape competitive positioning

Contemporary competitive dynamics in the MRD space are characterized by a blend of specialization and integration. Diagnostic developers and platform providers differentiate through analytical sensitivity, assay robustness, and ease of clinical workflow integration, while reagent suppliers compete on consistency, lot-to-lot reliability, and regulatory-compliant supply chains. Platform integrators and clinical laboratory networks are increasingly offering bundled services that combine instrumentation, software-enabled interpretation, and reporting templates that align with clinician decision needs.

Partnership models stand out as an accelerant: collaborations between diagnostic firms and biopharmaceutical sponsors enable co-development of companion MRD assays for therapeutic programs, while alliances with academic centers provide validation cohorts and real-world evidence. In parallel, some organizations are pursuing vertical integration-bringing assay development, manufacturing, and clinical service delivery under one operational umbrella-to reduce supply risk and capture greater downstream value. Service differentiation extends beyond analytical performance to include training, accreditation support, and post-market surveillance capabilities; the ability to demonstrate clinical utility through peer-reviewed evidence increasingly separates market leaders from niche players. These competitive behaviors suggest a maturing market where strategic alignment with clinical stakeholders and operational excellence determine long-term success.

Actionable and prioritized recommendations for industry leaders to accelerate adoption mitigate risk and align clinical evidence operational execution and payer engagement

Industry leaders seeking to accelerate MRD adoption should pursue a pragmatic set of actions that align clinical utility with operational feasibility. First, prioritize robust clinical evidence generation by embedding MRD endpoints into prospective therapeutic trials and by conducting real-world outcome studies that demonstrate how MRD-guided decisions alter patient trajectories. Second, strengthen supply chain resilience by qualifying alternative suppliers, building regional inventory buffers, and exploring localized production for high-risk components to mitigate tariff and logistics exposures.

Third, engage payers early to translate clinical benefit into reimbursement pathways, using cost-effectiveness models and phased coverage strategies tied to clinical indications. Fourth, invest in interoperable digital infrastructure that links laboratory results with electronic medical records and decision-support tools, thereby reducing clinician friction and ensuring timely therapeutic adjustments. Fifth, adopt flexible commercial models such as performance-based pricing or tiered service offerings to lower barriers for adoption in resource-constrained settings. Lastly, commit to workforce development through standardized training and accreditation programs that ensure consistent assay performance across decentralized testing environments. Collectively, these actions balance immediate operational needs with longer-term strategic positioning in a rapidly evolving diagnostic landscape.

Transparent research methodology explaining data sources expert engagements analytical frameworks and validation approaches used to derive insights on minimal residual disease testing

This analysis synthesizes evidence from a multi-pronged research approach designed to triangulate findings and reduce bias. The methodology combined systematic review of peer-reviewed literature, clinical guidelines, regulatory documents, and technical white papers with targeted primary research comprising interviews with clinical experts, laboratory directors, biopharma development leads, and supply chain specialists. Where available, assay performance data was compared across published validation studies and regulatory summaries to assess concordance and reproducibility.

Analytical frameworks included technology readiness assessment, value-chain mapping, and stakeholder impact analysis to understand where bottlenecks and opportunities converge. Regional policy and tariff impacts were modeled qualitatively through scenario analysis that considered procurement pathways, lead-time sensitivity, and the feasibility of regional manufacturing. Findings were iteratively validated through expert review sessions to reconcile divergent perspectives and to highlight limitations. Key methodological limitations include variability in published assay documentation, evolving regulatory guidance, and the inherent uncertainty around future policy adjustments; these factors were explicitly considered when framing conclusions and recommendations.

Concluding synthesis emphasizing the opportunities operational challenges and strategic priorities that will determine the future trajectory of minimal residual disease diagnostics

In summary, MRD testing stands at a pivotal juncture where analytical advances, clinical validation efforts, and commercial strategies converge to enable broader clinical utility. The diagnostic modalities available today collectively offer a toolkit that can be matched to disease biology and care delivery constraints, but successful scale-up depends on rigorous evidence generation, resilient supply chains, and payer engagement. Policy shifts such as tariffs and evolving reimbursement landscapes add complexity, requiring adaptive commercialization and operational planning.

For stakeholders across the ecosystem, the path forward centers on collaboration: clinical sites and laboratories must align on standardized practices, industry must invest in reproducible assay design and evidence, and payers and regulators should work with sponsors to define pathways that translate MRD detection into meaningful clinical decisions. Executing on these priorities will determine whether MRD fulfills its promise as a routine instrument of precision oncology or remains confined to specialized use cases. The balance of technical capability and system-level readiness will ultimately shape patient access and therapeutic innovation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Minimal Residual Disease Testing Market, by Test Type

  • 8.1. Cytogenetics
    • 8.1.1. Chromosomal microarray
    • 8.1.2. Fluorescence in situ hybridization (FISH)
  • 8.2. Flow Cytometry
    • 8.2.1. Multi-parameter flow cytometry
    • 8.2.2. Single-parameter flow cytometry
  • 8.3. Next-Generation Sequencing (NGS)
    • 8.3.1. Targeted sequencing
    • 8.3.2. Whole genome sequencing
  • 8.4. Polymerase Chain Reaction (PCR)
    • 8.4.1. Digital PCR
    • 8.4.2. Quantitative PCR

9. Minimal Residual Disease Testing Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Plasma
    • 9.1.2. Serum
  • 9.2. Bone Marrow
  • 9.3. Cerebrospinal Fluid (CSF)
  • 9.4. Tissue Biopsy
  • 9.5. Urine

10. Minimal Residual Disease Testing Market, by Application Areas

  • 10.1. Leukemia
    • 10.1.1. Acute Lymphoblastic Leukemia (ALL)
    • 10.1.2. Acute Myeloid Leukemia (AML)
    • 10.1.3. Chronic Lymphocytic Leukemia (CLL)
  • 10.2. Lymphoma
    • 10.2.1. Hodgkin's lymphoma
    • 10.2.2. Non-Hodgkin's lymphoma
  • 10.3. Multiple Myeloma
  • 10.4. Solid Tumors
    • 10.4.1. Breast cancer
    • 10.4.2. Colorectal cancer

11. Minimal Residual Disease Testing Market, by End-User Vertical

  • 11.1. Academic & Research Institutes
  • 11.2. Biopharmaceutical Companies
  • 11.3. Diagnostic Laboratories
  • 11.4. Hospitals

12. Minimal Residual Disease Testing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Minimal Residual Disease Testing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Minimal Residual Disease Testing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Minimal Residual Disease Testing Market

16. China Minimal Residual Disease Testing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Adaptive Biotechnologies Corporation
  • 17.6. Agilus Diagnostics Ltd.
  • 17.7. Amgen Inc.
  • 17.8. ARUP Laboratories
  • 17.9. AstraZeneca PLC
  • 17.10. Asuragen Inc. by Bio-Techne Corporation
  • 17.11. Bio-Rad Laboratories, Inc.
  • 17.12. Bristol-Myers Squibb Company
  • 17.13. C2I Genomics Inc.
  • 17.14. Cergentis B.V.
  • 17.15. Exact Sciences Corporation
  • 17.16. F. Hoffmann-La Roche Ltd.
  • 17.17. Genetron Holdings Limited
  • 17.18. GRAIL, LLC by Illumina, Inc.
  • 17.19. Guardant Health, Inc.
  • 17.20. Integrated DNA Technologies, Inc.
  • 17.21. Invivoscribe, Inc.
  • 17.22. Kite Pharma, Inc. by Gilead Sciences, Inc.
  • 17.23. Laboratory Corporation of America Holdings
  • 17.24. Mdxhealth BV
  • 17.25. MedGenome Inc
  • 17.26. Mission Bio, Inc.
  • 17.27. Myriad Genetics, Inc.
  • 17.28. Natera Inc.
  • 17.29. NeoGenomics Laboratories, Inc.
  • 17.30. OPKO Health, Inc.
  • 17.31. Quest Diagnostics incorporated
  • 17.32. Sysmex Corporation
  • 17.33. Veracyte, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHROMOSOMAL MICROARRAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTI-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SINGLE-PARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TARGETED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIGITAL PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY QUANTITATIVE PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY PLASMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SERUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BONE MARROW, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CEREBROSPINAL FLUID (CSF), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TISSUE BIOPSY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY URINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA (ALL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACUTE MYELOID LEUKEMIA (AML), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NON-HODGKIN'S LYMPHOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 143. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 208. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 221. GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 235. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 238. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 240. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 241. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 243. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 244. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 245. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 246. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 247. GCC MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 266. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 267. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 274. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 275. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY CYTOGENETICS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY FLOW CYTOMETRY, 2018-2032 (USD MILLION)
  • TABLE 278. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), 2018-2032 (USD MILLION)
  • TABLE 279. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), 2018-2032 (USD MILLION)
  • TABLE 280. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 281. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 282. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY APPLICATION AREAS, 2018-2032 (USD MILLION)
  • TABLE 283. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LEUKEMIA, 2018-2032 (USD MILLION)
  • TABLE 284. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY LYMPHOMA, 2018-2032 (USD MILLION)
  • TABLE 285. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY SOLID TUMORS, 2018-2032 (USD MILLION)
  • TABLE 286. G7 MINIMAL RESIDUAL DISEASE TESTING MARKET SIZE, BY END-USER VERTICAL, 2018-2032 (USD MILLION)
  • TABLE 287.